Bivalirudin is a direct thrombin inhibitor that functions by reversibly binding to the active site of thrombin. It is primarily utilized as an anticoagulant during percutaneous coronary intervention (PCI), particularly for patients with or at risk of heparin-induced thrombocytopenia (HIT). It offers rapid action and a short half-life, allowing for controllable anticoagulation.
Application & Function
Bivalirudin is a synthetic, 20-amino acid peptide that functions as a direct and reversible inhibitor of thrombin, playing a critical role in contemporary anticoagulation therapy. Its primary clinical utility and efficacy lie in the management of patients undergoing percutaneous coronary interventions (PCIs), such as angioplasty and stent placement, particularly in those with or at risk of heparin-induced thrombocytopenia (HIT).
Unlike indirect antithrombins, bivalirudin directly targets both circulating (fluid-phase) and clot-bound (fibrin-bound) thrombin. By inhibiting this key enzyme, bivalirudin effectively suppresses thrombus formation and propagation. Its action is rapid, predictable, and characterized by a short half-life (approximately 25 minutes), which allows for quick onset and relatively rapid reversal upon discontinuation.
Technical Specification
Frequently Asked Questions
1. What is the primary use of Bivalirudin?
Bivalirudin is used as an anticoagulant, specifically for patients undergoing percutaneous coronary intervention (PCI), including those at risk of heparin-induced thrombocytopenia (HIT).
2. What is the purity and grade of this Bivalirudin powder?
The product is Pharmaceutical Grade with a purity of over 99%, as tested by HPLC method.
3. How should the product be stored to maintain stability?
It is recommended to store Bivalirudin powder at -20°C to ensure its chemical stability and maintain a shelf life of up to 2 years.
4. What are the key advantages of Bivalirudin over heparin?
Bivalirudin provides a more predictable anticoagulant response, a shorter half-life (approx. 25 minutes), and does not trigger heparin-induced thrombocytopenia (HIT).
5. Does the product meet international standards?
Yes, the product is certified under GMP, ISO 9001, and complies with USP and BP standards.
6. What is the production capacity for this material?
The production capacity is approximately 2000kg per month to ensure steady supply.
SJ Medical
